Clinical Trial Update: A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update for NNC6019-0001 evaluating long-term treatment in people with transthyretin amyloid cardiomyopathy (ATTR-CM). The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• NNC6019-0001

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM) | Phase 2 | Status: ACTIVE_NOT_RECRUITING